Bank of America Securities Remains a Buy on Alnylam Pharma (ALNY)

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Alnylam Pharma, with a price target of $529.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Ahmad covers the Healthcare sector, focusing on stocks such as Neurocrine, Ascendis Pharma, and Rhythm Pharmaceuticals. According to TipRanks, Ahmad has an average return of 2.6% and a 52.93% success rate on recommended stocks.

In addition to Bank of America Securities, Alnylam Pharma also received a Buy from RBC Capital’s Luca Issi in a report issued on January 20. However, yesterday, TipRanks – xAI reiterated a Hold rating on Alnylam Pharma (NASDAQ: ALNY).

Based on Alnylam Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.25 billion and a net profit of $251.08 million. In comparison, last year the company earned a revenue of $500.92 million and had a GAAP net loss of $111.57 million

Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year. Earlier this month, Fitzgerald Kevin Joseph, the CSO & EVP, Head of Research of ALNY sold 1,510.00 shares for a total of $547,927.38.